Posted by Michael Wonder on 24 Sep 2025
Push for taxpayers to fund weight loss drugs for 500,000 Australians
23 September 2025 - Danish pharmaceutical giant Novo Nordisk has asked the Federal Government to subsidise its blockbuster weight loss drug Wegovy for up to 500,000 high risk Australians living with heart disease as well as obesity.
Novo Nordisk, which also makes Ozempic, has made the submission to the PBAC which, if successful, seeks to broaden the taxpayer funded application for the class of drugs known as GLP-1s beyond diabetes.
